ÀÇ·áÁø ã±â
¾Æ·¡ °Ë»öÀ» ÅëÇØ Á¤È®ÇÏ°í ºü¸£°Ô ÀÇ·áÁøÀ» °Ë»öÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áø·á°ú ¾È³»
[¹®ÀÇÀüÈ] 1577-9966
Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù. Ŭ¸¯ ½Ã ÇØ´ç Áø·á°úÀÇ ÀÚ¼¼ÇÑ »çÇ×À» º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
È£Èí±â¡¤¾Ë·¹¸£±â³»°ú
-
[±¹³»³í¹®]
Kartagener ÁõÈıº ȯÀÚÀÇ ±Þ¼ºÈ£ÈíºÎÀü-ºñħ½ÀÀû ȯ±âÄ¡·á·Î È£ÀüµÈ 1¿¹
¹é°æÇö, È«À±°æ, ÀÌ°¡¿µ, ±è¼Ò¸®, ¹Î°æÈÆ, ¹Ú¼ºÁÖ, ÀÌÈï¹ü, ÀÌ¿ëö, À̾ç±Ù
/ Kartagener ÁõÈıº ȯÀÚÀÇ ±Þ¼ºÈ£ÈíºÎÀü-ºñħ½ÀÀû ȯ±âÄ¡·á·Î È£ÀüµÈ 1¿¹
/ 30(1):17-24
/ 2006
-
[±¹³»³í¹®]
¸¸¼ºÆó¼â¼ºÆóÁúȯ°ú õ½ÄÀÇ °¨º°Áø´Ü¿¡¼ ¸ÞŸÄݸ° ±â°üÁöÀ¯¹ß°Ë»çÀÇ ÀÇÀÇ
È«À±°æ, Á¤Ä¡·®, ¹é°æÇö, ±è¼Ò¸®, ¹Î°æÈÆ, ¹Ú¼ºÁÖ, ÀÌÈï¹ü, ÀÌ¿ëö, À̾ç±Ù
/ ¸¸¼ºÆó¼â¼ºÆóÁúȯ°ú õ½ÄÀÇ °¨º°Áø´Ü¿¡¼ ¸ÞŸÄݸ° ±â°üÁöÀ¯¹ß°Ë»çÀÇ ÀÇÀÇ
/ 61(5):433-9.
/ 2006
-
[±¹³»³í¹®]
³»½Ã°æ Á¶Á÷ »ý°Ë ÈÄ ¹ß»ýÇÑ ±Þ¼º °Å´ë ÃâÇ÷¼º À§±Ë¾ç 1¿¹.
±è¼Ò¸®, ¹Î°æÈÆ, ³²»ó¿ì, ±èÇöö, Á¶¿ë±Ù, ±èÀÎÈñ, À̼öÅÃ, ¾Èµæ¼ö
/ ³»½Ã°æ Á¶Á÷ »ý°Ë ÈÄ ¹ß»ýÇÑ ±Þ¼º °Å´ë ÃâÇ÷¼º À§±Ë¾ç 1¿¹.
/ 31(2):111-5.
/ 2005
-
[±¹³»³í¹®]
°¢±â ´Ù¸¥ ¹æ¹ýÀ¸·Î Ä¡·áÇÑ Àå°£¸· Á¤¸Æ Ç÷ÀüÁõ 3¿¹.
Àå¿ë¹ü, ¹Î°æÈÆ, ±è¼º½Ä, ±èÀÎÈñ, À̼öÅÃ, ±è´ë°ï, À̽¿Á
/ °¢±â ´Ù¸¥ ¹æ¹ýÀ¸·Î Ä¡·áÇÑ Àå°£¸· Á¤¸Æ Ç÷ÀüÁõ 3¿¹.
/ 68(4):439-45
/ 2005
-
[SCI]
A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma.
Lee KS, Park HS, Park SJ, Kim SR, Min KH, Jin SM, Park KH, Kim UH, Kim CY, Lee YC.
/ A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma.
/ 68(5):1281-90.
/ 2005